Safety and efficacy of elsubrutinib or upadacitinib alone or in combination (ABBV-599) in patients with rheumatoid arthritis and inadequate response or intolerance to biological therapies: a multicentre, double-blind, randomised, controlled, phase 2 trial

Safety and efficacy of elsubrutinib or upadacitinib alone or in combination (ABBV-599) in patients with rheumatoid arthritis and inadequate response or intolerance to biological therapies: a multicentre, double-blind, randomised, controlled, phase 2 trial

Background ABBV-599 is a novel fixed-dose combination of the Bruton's tyrosine kinase (BTK) inhibitor elsubrutinib and the Janus kinase (JAK) inhibitor upadacitinib under investigation for the treatment of autoimmune diseases. We aimed to determine whether ABBV-599 could increase the treatment...

Full description

Bibliographic Details
Main Authors:	Fleischmann, R, Friedman, A, Drescher, E, Singhal, A, Cortes-Maisonet, G, Doan, T, Lu, W, Wang, Z, Nader, A, Housley, W, Cohen, S, Taylor, PC, Blanco, R
Format:	Journal article
Language:	English
Published:	Elsevier 2022

Similar Items

Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study
by: Roy Fleischmann, et al.
Published: (2024-07-01)

CFTR Rescue in Intestinal Organoids with GLPG/ABBV-2737, ABBV/GLPG-2222 and ABBV/GLPG-2451 Triple Therapy
by: Eyleen de Poel, et al.
Published: (2021-09-01)

PB2224: ABBV-744 ALONE OR IN COMBINATION WITH RUXOLITINIB OR NAVITOCLAX IN PATIENTS WITH MYELOFIBROSIS: A PHASE 1B STUDY
by: John Mascarenhas, et al.
Published: (2023-08-01)

Impact of upadacitinib or adalimumab as initial therapy on the achievement of 48-week treatment goals in patients with rheumatoid arthritis and inadequate response to methotrexate: Post hoc analysis of a phase 3 study
by: Mysler, E, et al.
Published: (2021)

The American Thoracic Society’s Spirometric Criteria Alone is Inadequate in Asthma Diagnosis
by: John A Gjevre, et al.
Published: (2006-01-01)

In vivo kinetics of Wolbachia depletion by ABBV-4083 in L. sigmodontis adult worms and microfilariae.
by: Marc P Hübner, et al.
Published: (2019-08-01)

Effectiveness of Upadacitinib in Patients with Atopic Dermatitis including those with Inadequate Response to Dupilumab and/or Baricitinib: Results from the BioDay Registry
by: Celeste M. Boesjes, et al.
Published: (2023-02-01)

Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT
by: Vibeke Strand, et al.
Published: (2019-12-01)

Correction to: Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT
by: Vibeke Strand, et al.
Published: (2020-06-01)

Construction services welding : examination paper no. 599 /
by: City and Guilds of London Institute
Published: ([19-)

Histerectomía laparoscópica en 1 599 pacientes
by: Javier Ernesto Barreras González, et al.

Transcriptome Analysis of Duck and Chicken Brains Infected with Aquatic Bird Bornavirus-1 (ABBV-1)
by: Phuc H. Pham, et al.
Published: (2022-10-01)

Upadacitinib for prurigo nodularis
by: Clara Muntaner-Virgili, MD, et al.
Published: (2024-06-01)

Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors
by: Fabrice Barlesi, et al.
Published: (2021-02-01)

Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs
by: Vibeke Strand, et al.
Published: (2019-12-01)

Discovery of ABBV-4083, a novel analog of Tylosin A that has potent anti-Wolbachia and anti-filarial activity.
by: Thomas W von Geldern, et al.
Published: (2019-02-01)

Preponderance of the oncogenic V599E and V599K mutations in <it>B-raf </it>kinase domain is enhanced in melanoma cutaneous/subcutaneous metastases
by: Hassanzadeh Judith, et al.
Published: (2005-06-01)

Model Informed Dosing Regimen and Phase I Results of the Anti‐PD‐1 Antibody Budigalimab (ABBV‐181)
by: John Powderly, et al.
Published: (2021-01-01)

Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patients
by: Junichiro Yuda, et al.
Published: (2023-10-01)

Upadacitinib for the treatment of psoriatic arthritis
by: Diogo Fonseca, et al.
Published: (2023-02-01)

P599: RARE GERMLINE VARIANTS IN ATM INFLUENCE THE PATHOGENESIS OF CLL
by: B. L. Lampson, et al.
Published: (2022-06-01)

PB2088: ABBV-383 IN COMBINATION WITH ANTI-CANCER REGIMENS IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: DOSE ESCALATION AND EXPANSION
by: Cesar Rodriguez Valdes, et al.
Published: (2023-08-01)

Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study
by: Joseph F Merola, et al.
Published: (2021-11-01)

1403-A PTPN2/N1 inhibitor ABBV-CLS-484 unleashes potent anti-tumor immunity
by: Wei Qiu, et al.
Published: (2023-11-01)

Effective treatment of alopecia universalis with oral upadacitinib
by: Soundos Youssef, MD, et al.
Published: (2023-01-01)

Refractory pityriasis rubra pilaris treated with upadacitinib
by: Eingun James Song, MD, et al.
Published: (2023-05-01)

Correction: Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study
Published: (2021-12-01)

Treatment of Discoid Lupus Erythematosus with Upadacitinib: A Case Report
by: Hu W, et al.
Published: (2023-10-01)

ABBV-744 as a potential inhibitor of SARS-CoV-2 main protease enzyme against COVID-19
by: Zeynab Fakhar, et al.
Published: (2021-01-01)

Immunogenicity of Sarilumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant to Disease-Modifying Antirheumatic Drugs
by: Alvin F. Wells, et al.
Published: (2019-05-01)

Intolerance of aloneness as a prospective predictor of suicidal ideation during COVID-19
by: Katie C. Lewis, et al.
Published: (2023-01-01)

Retreatment with upadacitinib in atopic dermatitis: experience in clinical practice
by: S. Martínez-Fernández, et al.
Published: (2023-12-01)

Management outcome(s) in eyes with retinoblastoma previously inadequately treated with systemic chemotherapy alone without focal therapy
by: Yacoub A Yousef, et al.
Published: (2017-01-01)

Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE
by: Mysler, E, et al.
Published: (2022)

US Patent 7,599,807 Compensating for frequency change in flowmeters
by: Tombs, M
Published: (2016)

Construction services welding (no.599) : schedules for the in-course assessment of practical work/
by: City and Guilds of London Institute
Published: ([19-)

Unilateral blaschkoid lichen planus successfully treated with upadacitinib
by: Chiara Rosenbaum, DO, MS, et al.
Published: (2024-03-01)

Correction: Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors
Published: (2019-06-01)

Case of recalcitrant amyopathic dermatomyositis treated with upadacitinib
by: Albert E. Zhou, MD, PhD, et al.
Published: (2024-12-01)

Successful Treatment of Disseminated Granuloma Annulare with Upadacitinib
by: Axel De Greef, et al.
Published: (2024-03-01)